Moderna, Inc. (MRNA)
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
Moderna ( MRNA ) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50.
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
Moderna Stock: How Far Can The Flu Shot Fly?
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increased by approximately $4.0 billion over the past 6 days and now sits at $20 billion.
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
Moderna's investigational flu vaccine moves forward in FDA review
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the update.
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many of which cited drug efficacy, safety and quality.
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
Moderna Stock Pops as FDA Application Moves Forward
Pharma giant Moderna Inc (NASDAQ:MRNA) is enjoying a boost today, after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review.
FDA reverses decision not to review Moderna's new flu vaccine
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
